Verastem (VSTM) Net Cash Flow (2011 - 2026)
Verastem (VSTM) posted quarterly Net Cash Flow of -$39.4 million for Q1 2026, down 237.17% year-over-year from $28.8 million in Q1 2025, and down 158.62% quarter-over-quarter from $67.3 million in Q4 2025.
Analysis
Verastem (VSTM) Net Cash Flow (2011 - 2026) Analysis & Trends
Verastem's Net Cash Flow history runs 16 years deep, the most recent figure standing at -$39.4 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 237.17% year-over-year to -$39.4 million; the TTM figure through Mar 2026 stood at $56.3 million (up 59.76% YoY), while the FY2025 annual figure was $116.2 million, up 1063.7% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$39.4 million, down from $67.3 million in the prior quarter.
- The five-year high for Net Cash Flow was $85.6 million in Q2 2023, with the low at -$87.6 million in Q3 2023.
- The 5-year median for Net Cash Flow is $15.2 million (2022), against an average of $9.0 million.
- The sharpest annual moves came in 2023 and 2025: Net Cash Flow slumped 676.46% in 2023, then jumped 4492.63% in 2025.
- Verastem's Net Cash Flow stood at -$3.6 million in 2022, then plunged by 392.65% to -$17.7 million in 2023, then plunged by 37.68% to -$24.4 million in 2024, then jumped by 376.24% to $67.3 million in 2025, then plunged by 158.62% to -$39.4 million in 2026.
- Business Quant data shows VSTM's Net Cash Flow at -$39.4 million in Q1 2026, $67.3 million in Q4 2025, and -$18.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -183.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 407.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -496,000.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Verastem | 814.94 Mn | 678.59 Mn | 36.32 Mn | -29.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -29.20 Mn |
| Mar 31, 2026 | -39.44 Mn |
| Dec 31, 2025 | 67.28 Mn |
| Sep 30, 2025 | -18.34 Mn |
| Jun 30, 2025 | 46.75 Mn |
| Mar 31, 2025 | 28.75 Mn |
| Dec 31, 2024 | -24.36 Mn |
| Sep 30, 2024 | 29.80 Mn |
| Jun 30, 2024 | 1.02 Mn |
| Mar 31, 2024 | 3.52 Mn |
| Dec 31, 2023 | -17.69 Mn |
| Sep 30, 2023 | -87.56 Mn |
| Jun 30, 2023 | 85.58 Mn |
| Mar 31, 2023 | 22.96 Mn |
| Dec 31, 2022 | -3.59 Mn |
| Sep 30, 2022 | 15.19 Mn |
| Jun 30, 2022 | 17.26 Mn |
| Mar 31, 2022 | 25.44 Mn |
| Dec 31, 2021 | -3.06 Mn |
| Sep 30, 2021 | -658,000.00 |